Absolutely not outside the context of a clinical trial. There are no data whatsoever on improved outcomes with this approach, and in fact, some older data with 1st gen EGFR TKIs show worse outcomes. In addition, I have tried it in a few patients and everyone relapsed rapidly with widely metastatic d...